CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

Real-world incidence and costs of serious infections and cardiovascular complications among patients with indolent non-Hodgkin lymphoma treated with first-line ...

A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial. Velcade (bortezomib), Rituxan ...

Please provide your email address to receive an email when new articles are posted on . The addition of copanlisib to rituximab extended PFS among patients with relapsed follicular lymphoma or ...

Liso-cel achieved a 95.5% overall response rate and a 62.1% complete response rate in MZL patients after at least two prior therapies. The two-year overall survival rate for patients treated with liso ...

Splenic marginal zone lymphoma (SMZL) is a rare, indolent B-cell lymphoma that principally involves the spleen, often extending to the bone marrow and peripheral blood, while nodal involvement remains ...

Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients ...

Long-term data showed that the addition of Imbruvica did not improve overall survival in patients with marginal zone lymphoma or mantle cell lymphoma. The pharmaceutical companies developing Imbruvica ...

Please provide your email address to receive an email when new articles are posted on . Janssen and Pharmacyclics intend to voluntarily withdraw the U.S. indications of ibrutinib for certain patients ...